These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38351809)

  • 61. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Status of minimal residual disease testing in childhood haematological malignancies.
    Campana D
    Br J Haematol; 2008 Nov; 143(4):481-9. PubMed ID: 18710378
    [TBL] [Abstract][Full Text] [Related]  

  • 63. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
    Shaver AC; Seegmiller AC
    Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
    Popov A; Henze G; Roumiantseva J; Budanov O; Verzhbitskaya T; Boyakova E; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Ponomareva N; Novichkova G; Fechina L; Karachunskiy A
    Leuk Res; 2023 Feb; 125():106998. PubMed ID: 36566537
    [No Abstract]   [Full Text] [Related]  

  • 65. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multiparameter flow cytometry in the diagnosis and management of acute leukemia.
    Peters JM; Ansari MQ
    Arch Pathol Lab Med; 2011 Jan; 135(1):44-54. PubMed ID: 21204710
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Progress of minimal residual disease studies in childhood acute leukemia.
    Campana D
    Curr Hematol Malig Rep; 2010 Jul; 5(3):169-76. PubMed ID: 20467922
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia.
    Qin X; Zhang MY; Liu WJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6885-6895. PubMed ID: 30402854
    [TBL] [Abstract][Full Text] [Related]  

  • 69. B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model.
    Shaver AC; Greig BW; Mosse CA; Seegmiller AC
    Am J Clin Pathol; 2015 May; 143(5):716-24. PubMed ID: 25873506
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Characteristics and monitoring of minimal residual disease in patients with T acute lymphoid leukemia by flow cytometry with two 4-color combinations of fluorescent antibodies].
    Li L; Yuan XJ; Xu C; Jiang LM; Shen LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1103-9. PubMed ID: 23114128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunologic monitoring in adults with acute lymphoblastic leukemia.
    Vidriales MB; Orfao A; San-Miguel JF
    Curr Oncol Rep; 2003 Sep; 5(5):413-8. PubMed ID: 12895394
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
    Brüggemann M; Gökbuget N; Kneba M
    Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
    Elorza I; Palacio C; Dapena JL; Gallur L; Sánchez de Toledo J; Díaz de Heredia C
    Haematologica; 2010 Jun; 95(6):936-41. PubMed ID: 20179088
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents.
    Bouriche L; Bernot D; Nivaggioni V; Arnoux I; Loosveld M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):158-163. PubMed ID: 30698327
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Minimal residual disease monitoring by flow cytometry.
    Vidriales MB; San-Miguel JF; Orfao A; Coustan-Smith E; Campana D
    Best Pract Res Clin Haematol; 2003 Dec; 16(4):599-612. PubMed ID: 14592645
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.